AIM ImmunoTech Inc. (AIM)

NYSE American - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

0.7580

-0.0271

(-3.45%)

As of 03:08PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	0.7851
Open	0.7800
Bid	0.7553 x 1400
Ask	0.7600 x 1400
Day's Range	0.7513 - 0.7800
52 Week Range	0.5500 - 2.2000
Volume	69,478
Avg. Volume	164,283

Market Cap	36.421M
Beta (5Y Monthly)	-0.46
PE Ratio (TTM)	N/A
EPS (TTM)	-0.4040
Earnings Date	Nov 09, 2022 - Nov 14, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	5.67

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AIM

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

AIM ImmunoTech Inc.
Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.
Rating
Fair Value
Economic Moat
5 days agoArgus Research

All

Business Wire
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
OCALA, Fla., August 15, 2022--AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement regarding the outcome of a hearing in the Delaware Court of Chancery concerning a motion for a temporary restraining order ("TRO") sought by activist shareholder Jonathan Jorgl:
GlobeNewswire
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
AIM CEO Thomas K. Equels AIM CEO Thomas K. Equels – On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Capital position expected to fund company through end of 2023 OCALA, Fla., Aug. 15, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on
- CareRx Reports Continued Strong Growth for the Second Quarter of 2022
  CNW Group
- ZipRecruiter Announces Second Quarter 2022 Results
  Business Wire
GlobeNewswire
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions Daniel Peterson, MD, the Sierra Internal Medicine in Incline Village, Nev. Daniel Peterson, MD, the Sierra Internal Medicine in Incline Village, Nev. Charles Lapp, MD, the Hunter-Hopkins Center in Charlotte, N.C. Charles Lapp, MD, the Hunter-Hopkins Center in Charlotte, N.C. OCALA, Fla., July 28, 2